Paper42136397
Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial.
Chang VWL and 11 others. Clin Infect Dis, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial. Papers, record 42136397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42136397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Three Months of Weekly Rifapentine and Isoniazid Versus Four Months of Daily Rifampicin for Tuberculosis Infection: A Randomized Controlled Trial.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Rifampin | Major topic |
| Isoniazid | Major topic |
| Antitubercular Agents | Major topic |
| Tuberculosis | Major topic |
| Humans | |
| Female | |
| Male | |
| Adult | |
| Middle Aged | |
| Australia | |
| Treatment Outcome | |
| Drug Administration Schedule | |
| Drug Therapy, Combination |
Source PubMed
References14
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 25904367 | Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. | Clin Infect Dis | 2015 | https://conductscience.org/library/papers/25904367 | PubMed |
| 2 | 27522233 | The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. | Lancet Infect Dis | 2016 | https://conductscience.org/library/papers/27522233 | PubMed |
| 3 | 20091503 | Treatment of latent tuberculosis infection in HIV infected persons. | Cochrane Database Syst Rev | 2010 | https://conductscience.org/library/papers/20091503 | PubMed |
| 4 | 11069825 | Incidence of tuberculosis among a cohort of tuberculin-positive refugees in Australia: reappraising the estimates of risk. | Am J Respir Crit Care Med | 2000 | https://conductscience.org/library/papers/11069825 | PubMed |
| 5 | 29224209 | SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication. | Intern Med J | 2017 | https://conductscience.org/library/papers/29224209 | PubMed |
| 6 | 30865794 | One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30865794 | PubMed |
| 7 | 30067931 | Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30067931 | PubMed |
| 8 | 25580725 | Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. | JAMA Pediatr | 2015 | https://conductscience.org/library/papers/25580725 | PubMed |
| 9 | 21732833 | New regimens to prevent tuberculosis in adults with HIV infection. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21732833 | PubMed |
| 10 | 22150035 | Three months of rifapentine and isoniazid for latent tuberculosis infection. | N Engl J Med | 2011 | https://conductscience.org/library/papers/22150035 | PubMed |
| 11 | 30067928 | Safety and Side Effects of Rifampin versus Isoniazid in Children. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30067928 | PubMed |
| 12 | 25111745 | Treatment of latent tuberculosis infection: a network meta-analysis. | Ann Intern Med | 2014 | https://conductscience.org/library/papers/25111745 | PubMed |
| 13 | 36966788 | Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. | Lancet Respir Med | 2023 | https://conductscience.org/library/papers/36966788 | PubMed |
| 14 | 27243774 | Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. | AIDS | 2016 | https://conductscience.org/library/papers/27243774 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42136397
GET https://conductscience.org/api/papers/v1/42136397/authors